JP2021512923A - 医薬組成物、組成物の添加剤及び組成物の使用 - Google Patents
医薬組成物、組成物の添加剤及び組成物の使用 Download PDFInfo
- Publication number
- JP2021512923A JP2021512923A JP2020542883A JP2020542883A JP2021512923A JP 2021512923 A JP2021512923 A JP 2021512923A JP 2020542883 A JP2020542883 A JP 2020542883A JP 2020542883 A JP2020542883 A JP 2020542883A JP 2021512923 A JP2021512923 A JP 2021512923A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- cbd
- sint
- cannabidiol
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 239000000654 additive Substances 0.000 title 1
- 241001465754 Metazoa Species 0.000 claims abstract description 70
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims abstract description 46
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims abstract description 43
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims abstract description 43
- 229950011318 cannabidiol Drugs 0.000 claims abstract description 43
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims abstract description 43
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 15
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 14
- 201000001119 neuropathy Diseases 0.000 claims abstract description 14
- 230000007823 neuropathy Effects 0.000 claims abstract description 14
- 230000000324 neuroprotective effect Effects 0.000 claims abstract description 14
- 208000033808 peripheral neuropathy Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 10
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 5
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 5
- 239000003921 oil Substances 0.000 claims description 51
- 235000019198 oils Nutrition 0.000 claims description 51
- -1 cannabidiol acid methyl ester Chemical class 0.000 claims description 10
- 241000196324 Embryophyta Species 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 235000005687 corn oil Nutrition 0.000 claims description 6
- 239000002285 corn oil Substances 0.000 claims description 6
- 239000007903 gelatin capsule Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 208000000094 Chronic Pain Diseases 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 206010003805 Autism Diseases 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 4
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 claims description 4
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims description 4
- IRMPFYJSHJGOPE-UHFFFAOYSA-N Olivetol Natural products CCCCCC1=CC(O)=CC(O)=C1 IRMPFYJSHJGOPE-UHFFFAOYSA-N 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 4
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 4
- HCAWPGARWVBULJ-IAGOWNOFSA-N delta8-THC Chemical compound C1C(C)=CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 HCAWPGARWVBULJ-IAGOWNOFSA-N 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 239000002600 sunflower oil Substances 0.000 claims description 4
- 235000019489 Almond oil Nutrition 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims description 3
- 241000016649 Copaifera officinalis Species 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 3
- 241000283074 Equus asinus Species 0.000 claims description 3
- 235000019493 Macadamia oil Nutrition 0.000 claims description 3
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 3
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 3
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 3
- 241000237502 Ostreidae Species 0.000 claims description 3
- 235000019482 Palm oil Nutrition 0.000 claims description 3
- 244000288157 Passiflora edulis Species 0.000 claims description 3
- 235000000370 Passiflora edulis Nutrition 0.000 claims description 3
- 235000019483 Peanut oil Nutrition 0.000 claims description 3
- 244000294611 Punica granatum Species 0.000 claims description 3
- 235000014360 Punica granatum Nutrition 0.000 claims description 3
- 239000008168 almond oil Substances 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 235000021302 avocado oil Nutrition 0.000 claims description 3
- 239000008163 avocado oil Substances 0.000 claims description 3
- 229960003453 cannabinol Drugs 0.000 claims description 3
- 239000000828 canola oil Substances 0.000 claims description 3
- 235000019519 canola oil Nutrition 0.000 claims description 3
- 235000019864 coconut oil Nutrition 0.000 claims description 3
- 239000003240 coconut oil Substances 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 3
- 239000010647 garlic oil Substances 0.000 claims description 3
- 239000008169 grapeseed oil Substances 0.000 claims description 3
- 235000021388 linseed oil Nutrition 0.000 claims description 3
- 239000000944 linseed oil Substances 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 239000010469 macadamia oil Substances 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 235000019488 nut oil Nutrition 0.000 claims description 3
- 239000010466 nut oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 3
- 235000020636 oyster Nutrition 0.000 claims description 3
- 230000036407 pain Effects 0.000 claims description 3
- 239000002540 palm oil Substances 0.000 claims description 3
- 239000000312 peanut oil Substances 0.000 claims description 3
- 239000010667 rosehip oil Substances 0.000 claims description 3
- 239000008159 sesame oil Substances 0.000 claims description 3
- 235000011803 sesame oil Nutrition 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 244000028344 Primula vulgaris Species 0.000 claims description 2
- 235000016311 Primula vulgaris Nutrition 0.000 claims description 2
- 235000019498 Walnut oil Nutrition 0.000 claims description 2
- 239000010472 acai oil Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 235000012716 cod liver oil Nutrition 0.000 claims description 2
- 239000003026 cod liver oil Substances 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 239000008170 walnut oil Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 36
- 238000002360 preparation method Methods 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000000902 placebo Substances 0.000 description 33
- 229940068196 placebo Drugs 0.000 description 33
- 230000000694 effects Effects 0.000 description 32
- 241000700159 Rattus Species 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 26
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 25
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 20
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 239000013642 negative control Substances 0.000 description 17
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 14
- 230000001154 acute effect Effects 0.000 description 12
- 238000012347 Morris Water Maze Methods 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 230000003542 behavioural effect Effects 0.000 description 10
- 229930003827 cannabinoid Natural products 0.000 description 9
- 239000003557 cannabinoid Substances 0.000 description 9
- 229960003638 dopamine Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 101710138657 Neurotoxin Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 229940065144 cannabinoids Drugs 0.000 description 6
- 229960004397 cyclophosphamide Drugs 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 239000002581 neurotoxin Substances 0.000 description 6
- 231100000618 neurotoxin Toxicity 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 238000010953 Ames test Methods 0.000 description 5
- 231100000039 Ames test Toxicity 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 231100000170 comet assay Toxicity 0.000 description 5
- 238000003927 comet assay Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000265 homogenisation Methods 0.000 description 5
- 231100000299 mutagenicity Toxicity 0.000 description 5
- 230000007886 mutagenicity Effects 0.000 description 5
- 238000012346 open field test Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000036387 respiratory rate Effects 0.000 description 5
- 238000002672 stereotactic surgery Methods 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- YCSBALJAGZKWFF-UHFFFAOYSA-N anthracen-2-amine Chemical compound C1=CC=CC2=CC3=CC(N)=CC=C3C=C21 YCSBALJAGZKWFF-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000006742 locomotor activity Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000041 toxicology testing Toxicity 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 101100243025 Arabidopsis thaliana PCO2 gene Proteins 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000001061 Dunnett's test Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000002565 electrocardiography Methods 0.000 description 3
- 231100000025 genetic toxicology Toxicity 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003601 intercostal effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000003523 substantia nigra Anatomy 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 206010001541 Akinesia Diseases 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 208000009132 Catalepsy Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 206010047853 Waxy flexibility Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- PWOQRKCAHTVFLB-UHFFFAOYSA-N cyclophosphamide hydrate Chemical compound O.ClCCN(CCCl)P1(=O)NCCCO1 PWOQRKCAHTVFLB-UHFFFAOYSA-N 0.000 description 2
- 230000002559 cytogenic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000007674 genetic toxicity Effects 0.000 description 2
- 231100000024 genotoxic Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009184 walking Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- YYVFXSYQSOZCOQ-UHFFFAOYSA-N Oxyquinoline sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C[NH+]=C2C(O)=CC=CC2=C1.C1=C[NH+]=C2C(O)=CC=CC2=C1 YYVFXSYQSOZCOQ-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010036040 Polychromasia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CGQCWMIAEPEHNQ-UHFFFAOYSA-N Vanillylmandelic acid Chemical compound COC1=CC(C(O)C(O)=O)=CC=C1O CGQCWMIAEPEHNQ-UHFFFAOYSA-N 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960001335 benserazide hydrochloride Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 108010002255 deoxyhemoglobin Proteins 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000006153 eosin methylene blue Substances 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 101150113423 hisD gene Proteins 0.000 description 1
- 101150032598 hisG gene Proteins 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- JDBJJCWRXSVHOQ-UTONKHPSSA-N methanesulfonic acid;(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound CS(O)(=O)=O.C1=CC=C2[C@H](NCC#C)CCC2=C1 JDBJJCWRXSVHOQ-UTONKHPSSA-N 0.000 description 1
- RQGAOBDPFOADCM-UHFFFAOYSA-N methyl 2,4-dihydroxy-6-pentylbenzoate Chemical compound CCCCCC1=CC(O)=CC(O)=C1C(=O)OC RQGAOBDPFOADCM-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- FYTRVVJHEWUARG-UHFFFAOYSA-N n-(2-aminophenyl)nitramide Chemical compound NC1=CC=CC=C1N[N+]([O-])=O FYTRVVJHEWUARG-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229960001956 rasagiline mesylate Drugs 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000009183 running Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021127 solid diet Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、50〜400mgの合成起源の活性成分カンナビジオールを、最大で0.06%のカンナビノール、最大で0.06%のデルタ‐8‐テトラヒドロカンナビノール、最大で0.06%のデルタ‐9‐テトラヒドロカンナビノール、最大で0.06%のカンナビジオール酸メチルエステル、最大で0.06%のメンタジエノール、及び最大で0.06%のオリベトール酸メチルとともに含む医薬組成物を開示する。本発明はまた、カンナビジオールが100〜1750mg/日の範囲の用量で経口投与される、その神経保護作用による神経障害を治療するための薬物の調製におけるこの組成物の使用を開示する。
合成カンナビジオールを得るプロセスにおいて、以下の工程を含む:
a.カンナビジオール酸メチルエステルを得るための、化合物メンタジエノールとオリベトール酸メチルから始まる縮合反応。
b.以前に得られたカンナビジオール酸メチルエステルから出発して、粗製合成カンナビジオールを得るための脱炭酸鹸化反応。
c.得られた粗カンナビジオールの濾過。
d.得られた粗カンナビジオールの結晶化。
e.得られた粗カンナビジオールの再結晶。
f.得られた粗カンナビジオールの乾燥。
製造プロセスは、固体の医薬品形態の調製のための通常の機器、たとえば、振動ふるい、医薬品ミキサー(「V」ミキサー、ダブルコーンミキサー、BINミキサー、及び/又は高剪断ミキサー)、流動床、ストーブ、ローラーコンパクター、回転式医薬品プレス及びカプセル化装置、コーティング機(ドリルパン及び粉振り器)、攪拌機、コロイド/ultra‐turraxミルを使用する。
a.有効成分を溶媒又は共溶媒に溶解し、その後、他のアジュバントを添加し、加熱して、又は加熱せずに均質化する、及び/又は
b.有効成分を溶剤又は共溶剤に溶解した後、他のアジュバントを添加し、均質化し、経皮投与のためのサポート内に組み込む、及び/又は
c.有効成分を溶媒又は共溶媒に溶解又は懸濁し、その後、他のアジュバントを添加し、均質化し、経鼻及び/又は肺投与のサポート内に組み込む、及び/又は
d.有効成分と賦形剤の添加、均質化、及びカプセル化、及び/又は
e.有効成分と賦形剤の添加、微小球形化、均質化、及びカプセル化。
f.有効成分と賦形剤の添加、微小球形化、均質化と圧縮、及び/又は
g.有効成分と賦形剤の添加、均質化、圧縮、コーティング、及び/又は
h.有効成分と賦形剤の添加、均質化、造粒、及び圧縮、
i.リポソーム系、ナノ粒子及び/又はナノカプセルへの活性物質の組み込み。
単回投与(急性)毒性研究は、ラット及びマウス(雄及び雌)の異なる群を用いて、OECD(2001)及びANVISA(2013)によって推奨された手順に従って行われた。
使用したCBDの用量は、薬物開発に必要な非臨床毒性学及び薬理学的安全性研究を実施するためのガイド(ANVISA、2013年、バージョン1.2)-短期プロトコルから決定された。次の試験が実行された。
小核試験(Schmid、1976)を実施するために、ラットの異なる群(雄及び雌;n=10)は、CBD(500、1000及び2000mg/kg)の3回用量を経口投与された。陰性対照群は強制経口投与によりプラセボを投与され、陽性対照は腹腔内にシクロホスファミド一水和物(20mg/kg‐Sigma‐Aldrich)で処置された。処置終了後24時間(シクロホスファミド)及び48時間(CBD‐SINT及びビヒクル)後、断頭により動物を安楽死させた。大腿骨を取り除き、近位骨端を取り除いて髄管を露出させ、13x4.5mmの針と3mLのNaCl溶液(150mM)を用いて骨髄を取り除き、髄管をNaCl溶液で洗浄した。材料をガラス管に移し、1000rpm/5分で遠心分離した。遠心分離後、上澄みを廃棄し、沈殿物を4%ホルムアルデヒド溶液で再懸濁し、パスツールピペットを使用してわずかに均質化した。この細胞懸濁液を一滴、きれいな乾いたスライドの上に置き、次いで塗抹標本を作製した。スライドを室温で乾燥させ、24時間後、リーシュマンエオシン‐メチレンブルーで染色し、顕微鏡分析にかけた。小核の数を決定するために、光学顕微鏡を使用して400倍の倍率で、動物ごとに2000個の多色赤血球(各スライドで1000個)をカウントした。スライドの分析はブラインドであり、一人の評価者によって行われた。
コメットアッセイを実施するために、ラットの異なる群(雄及び雌;n=10)は、3回の用量のCBD‐SINT(500、1000及び2000mmg/kg)を経口投与された。陰性対照群は強制経口投与によりプラセボを投与され、陽性対照は腹腔内にシクロホスファミド一水和物(20mg/kg‐Sigma‐Aldrich)で処置された。処置の終了後、24時間(シクロホスファミド)及び48時間(CBD‐SINT及びビヒクル)の後、動物を安楽死させる前に末梢血のサンプルを採取した。DNA損傷の評価のために電気泳動ゲル上で実行される細胞を含むスライドの取得は、Klaudeら(1996)によって記載された技術に従って行われた。37℃で120μLの5%LMPアガロースと混合して得られた合計10μLの細胞懸濁液を、通常のアガロース(1.5%)でプレカバーされたスライドに載せ、アガロース硬化のために4℃で10分間(カバースリップで覆って)冷蔵した。スライドに細胞を加えた後、さらなるDNA損傷を防ぐために、直接光への曝露(照射)を避けた。カバースリップを注意深く取り除き、スライドを冷蔵庫(4℃)の溶解液に1時間保存した。溶解時間後、スライドを取り出して水平電気泳動槽に入れ、アルカリ電気泳動バッファーを加えて覆い、その後、DNA変性のために槽を氷の入った容器(4°C)に25分間浸した。次に、25ボルト及び300ミリアンペアで電気泳動を開始した。走行時間は約25分であった。電気泳動後、スライドを取り外し、5mLの緩衝液で5分間中和し、この手順を2回繰り返した。スライドを乾燥させた後、それらをエタノールで5分間固定し、分析まで冷蔵庫に保管した。分析のために、スライドを臭化エチジウム100μLで染色し、カバースリップで覆い、約5分後に分析した。DNA損傷を視覚化するために、515〜560nmの励起フィルターと590nmのバリアフィルターを備えた蛍光顕微鏡を使用して、スライドを400倍の倍率で観察した。各動物から100個の細胞を分析した。
AMES試験では、サルモネラ・チフィムリウムのTA100及びTA98株を使用した。DNAの塩基対置換を引き起こす変異原を検出するTA100株は、最初のヒスチジン生合成酵素をコードするhisG遺伝子(hisG46)に突然変異を含み、CGペアが逆転のための好ましいポイントとなる。TA98株は、hisD遺伝子に8つの反復GC残基を逆転させる変異があり、変異原性化合物を検出してDNAリーディングフレームをシフトさせる。Maron and Ames(1983)によって開発されたプレートへの直接取り込みの方法論によれば、異なる濃度のCBD‐SINT(375、250、125及び62.5μg/プレート)を、0.1mLの細菌培養液と2mLの表面寒天(トップアガー)とともに混合し、微量のヒスチジンとビオチンを補充した。代謝活性化を伴う試験では、ラット肝臓の均質化ミクロソーム画分S9 0.5mL(酵素誘導剤arochloror 1254で処理された齧歯類の肝臓から調製された、補因子が補充されたミトコンドリア後画分)(MOLTOX‐Molecular Toxicology、米国)が追加された。陰性対照として、二回蒸留水(ビヒクル)を使用した。TA98の陽性対照として、DMSOに溶解した4‐ニロフェニレンジアミン(NPD)を10μg/プレートの濃度で使用した。TA100株については、1.25μg/プレートの濃度で再蒸留水に溶解したアジ化ナトリウムを、代謝活性化なしの試験で使用した。代謝活性化を伴うアッセイでは、2‐アントラミン(2‐ANTR)を変異原として濃度3μg/プレートでTA100及びTA98に使用した。各チューブの内容物をわずかに均質化し、最小限のグリコシル化寒天を含むプレートの表面に注いだ。トップアガーが固化した後、プレートを37℃で48時間インキュベートした。この期間の後、プレートあたりの反転コロニーの数を数えた。アッセイは三重に行った。
雄のニュージーランドウサギ(群あたりn=6)を薬理学的安全性試験に使用した。すべての試験は経口で行われ(ヒトに推奨される経路)、調査されたパラメーターはCBD‐SINTの単回投与後に決定された。CBD‐SINT用量は、ヒト患者で使用された平均用量(25mg/kg)からの相対成長外挿によって決定された。
中枢神経系への効果は、修正されたアーウィン試験(Roux et al.,2005)に従って雄ウサギで評価された。
6時間の絶食後、3回の用量のCBD‐SINT(17、51及び170mg/kg)を強制飼養により雄ウサギの異なる群に投与した。プラセボを対照群に投与した(1mL/kg)。処置の1時間後、すべてのウサギは腹臥位で意識を保った。呼吸数は、Kofranyi‐Michaelis呼吸計を使用して決定された(Murphy、2002)。動脈血ガス分析のために、動脈血サンプルを耳の中心動脈から採取し、すぐに処理した。以下のすべてのパラメーターは、Cobas b 221マルチパラメトリック血液ガス分析装置(Roche Diagnostics、Rotkreuz、スイス)で決定された:pH、PCO2(mmHg)、PO2(mmHg)、SO2(%)、Htc(%)、tHb(g/dL)、Na+(mmol/L)、K+(mmol/L)、Ca2+(mmol/L)、Cl−(mmol/L)、グルコース(mg/dL)、乳酸塩(mmol/L)、O2Hb(%)、HHb(%)、P50(mmHg)、H+(nmol/L)、BE(nmol/L)、BEecf(nmol/L)、BB(mmol/L)、cHCO3(mmol/L)、ctCO2(B)(mmol/L)、ctCO2(P)(mmol/L)、及びctO2(体積%)。
心臓血管系への効果は、2つの試験により評価された:
群あたりの動物の数は10の被験体であった。この数は、国際的に認められ、科学的に検証されたプロトコルに基づいて推定された。CBD‐SINT製剤の用量は、ヒト患者で使用された平均用量(600mg/日、70kgの個人では約9mg/kgを表す)から相対測定外挿法により決定され、ラットで平均用量〜36mg/kgCBDを得た。
‐MPTP+プラセボ
‐MPTP+CBD‐SINT 12mg/kg
‐MPTP+CBD‐SINT 36mg/kg
‐MPTP+CBD‐SINT 120mg/kg
‐シャム+プラセボ
‐ナイーブ
‐6‐OHDA+プラセボ
‐6‐OHDA+CBD‐SINT 12mg/kg
‐6‐OHDA+CBD‐SINT 36mg/kg
‐6‐OHDA+CBD‐SINT 120mg/kg
‐シャム+プラセボ
‐ナイーブ
動物をオープンフィールドの中心円上に置き、その行動を5分間評価した。この評価には、歩行の頻度(4本の脚がすべて部屋に入る)、立ち上がる(アリーナの床に対して体幹が垂直になり、後脚でのみサポート)、不動の期間(自発運動なし、完全に麻痺している)及び潜在時間(動物がアリーナの中心円に配置されてから動き始めるのにかかる時間)が含まれていた。各動物を個別に評価し、動物間で5%アルコール溶液でデバイスを洗浄した(図15)。
すべての実験群は、モリス水迷路で試験された。
最後の一連の実験の後、MPTPによる黒質線条体処置からの動物及びそのそれぞれの対照を断頭により安楽死させた。ドーパミン(DA)とその代謝産物3,4‐ジヒドロキシフェニル酢酸(DOPAC)及びホモバニリン酸(HVA)のレベルは、Luo et al.(2009)により、電気化学検出器を備えた高速液体クロマトグラフィー(HPLC‐ECD)によって測定された。
結果は、MPTPの注入の24時間後、陰性対照群(C−:MPTP+プラセボ)は、動きの開始に対する潜在時間が有意に増加したことを示した。実際、ナイーブ群及びシャム群と比較して、この群では自発運動量が有意に低下していることがわかり、ラットのMPTPモデルがモデルに期待されるように動物の活動量の低下をもたらしたことを示す。
図21(A及びB)に示されるように、MPTP+プラセボ群(陰性対照;C−)のラットは、動物のナイーブ又はシャム群と比較した場合、プラットフォームを発見するための潜在時間の有意な増加を示した。これらの変化は、トレーニングの5日目から始まり、10日目まで続いた。
異なる実験群間のドーパミン、DOPAC及び線条体AVMのレベルについて見出された値を図22に示す。
データは、損傷の35日後、陰性対照群が、ナイーブ群及びシャム群と比較して、このパラメーターの有意な増加を示したことを示す。
図27は、モリス水迷路試験でプラットフォームを見つけるために、6‐OHDA及びそのそれぞれの対照で処置された異なる実験群に必要な潜在時間を示す。
Claims (13)
- 合成起源のカンナビジオール、最大で0.06%のカンナビノール、最大で0.06%のデルタ‐8‐テトラヒドロカンナビノール、最大で0.06%のデルタ‐9‐テトラヒドロカンナビノール、最大で0.06%のカンナビジオール酸メチルエステル、最大で0.06%のメンタジエノール及び最大で0.06%のオリベトール酸メチルを含むことを特徴とする医薬組成物。
- 合成起源のカンナビジオールが50〜400mgの範囲であることを特徴とする、請求項1に記載の組成物。
- 硬ゼラチンカプセル、錠剤、コーティング錠、口腔内崩壊錠、発泡錠、ロゼンジ、シロップ、懸濁液及び/又は溶液の経口医薬形態、特に軟ゼラチンカプセルであることを特徴とする、請求項1に記載の組成物。
- 植物、動物又は鉱物起源の油又はそれらの組み合わせを含むことを特徴とする、請求項1に記載の組成物のための賦形剤。
- 油が、ブドウ種子油、ゴマ油、トウモロコシ油、大豆油、オリーブ油、ヒマワリ油、キャノーラ油、クルミ油、亜麻仁油、アボカド油、ミント油、ピーナッツ油、水素化ヒマシ油、ココナッツ油、アサイ油、アンディロバ油、ババス油、ブリチ油、ブラジルナッツ油、コパイバ油、パッションフルーツ油、プラカキシ油、パタウア油、トリグリセリド、プリムローズ油、ベニバナ油、アーモンド油、ルリヂサ油、ザクロ種子油、シーバックソーン油、ニンニク油、オキアミ油、タラ肝油、パーム油、魚油、硬化ヒマシ油、マカダミア油、ローズヒップ油、綿油、又はそれらの組み合わせを含む群から選択されることを特徴とする、請求項4に記載の賦形剤。
- 油性溶媒がトウモロコシ油を含むことを特徴とする、請求項5に記載の賦形剤。
- 神経保護作用を有することを特徴とする、請求項1〜3のいずれか一項に記載の組成物の使用。
- 投与が100〜1750mg/日の用量であることを特徴とする、請求項7に記載の組成物の使用。
- 神経障害を治療するための医薬を調製するためのものであることを特徴とする、請求項1〜3のいずれか一項に記載の組成物の使用。
- 神経障害が難治性てんかん、てんかん、統合失調症、睡眠障害、心的外傷後障害、アルツハイマー病、不安神経症、うつ病、双極性障害、神経障害性疼痛、慢性疼痛緩和、自閉症、慢性疼痛緩和、及びパーキンソン病であることを特徴とする請求項9に記載の組成物の使用。
- 神経障害がパーキンソン病であることを特徴とする、請求項9に記載の使用。
- カンナビジオールの用量が300〜850mg/日であることを特徴とする、請求項9に記載の使用。
- 用量が単回用量であるか、又は一日を通して分割されることができることを特徴とする、請求項7又は9に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR102018002843A BR102018002843A2 (pt) | 2018-02-09 | 2018-02-09 | composição farmacêutica e uso da mesma |
BR102018002843-0 | 2018-02-09 | ||
PCT/BR2019/050040 WO2019153064A1 (pt) | 2018-02-09 | 2019-02-11 | Composição farmacêutica, excipiente para a composição e uso da composição |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021512923A true JP2021512923A (ja) | 2021-05-20 |
Family
ID=67548108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020542883A Pending JP2021512923A (ja) | 2018-02-09 | 2019-02-11 | 医薬組成物、組成物の添加剤及び組成物の使用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11389423B2 (ja) |
EP (1) | EP3750537A4 (ja) |
JP (1) | JP2021512923A (ja) |
CN (1) | CN111936133A (ja) |
AU (1) | AU2019217668A1 (ja) |
BR (2) | BR102018002843A2 (ja) |
CA (1) | CA3096962A1 (ja) |
WO (1) | WO2019153064A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
WO2022103635A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
CN112386589B (zh) * | 2021-01-21 | 2021-03-23 | 龙麻(上海)医药研发有限责任公司 | 一种抗焦虑/抗抑郁药用组合物及其用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160256410A1 (en) * | 2015-03-02 | 2016-09-08 | Afgin Pharma, Llc | Topical regional neuro-affective therapy in mammals with cannabinoids |
US20160317468A1 (en) * | 2015-04-28 | 2016-11-03 | Raman Sankar | Uses of cannabidiol for treatment of infantile spasms |
JP2017519742A (ja) * | 2014-05-29 | 2017-07-20 | インシス・ファーマ・インコーポレーテッド | 安定なカンナビノイド製剤 |
JP2020532590A (ja) * | 2017-09-01 | 2020-11-12 | ピュアフォーム グローバル インコーポレイテッド | 合成カンナビジオール組成物およびその製造方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7025992B2 (en) | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
WO2009020666A1 (en) | 2007-08-06 | 2009-02-12 | Insys Therapeutics Inc. | Oral cannabinoid liquid formulations and methods of treatment |
RU2016129536A (ru) | 2013-10-31 | 2018-01-31 | Фулл Спектрум Лабораториз, Лтд. | Препараты на основе терпенов и каннабиноидов |
US20160367496A1 (en) * | 2014-05-29 | 2016-12-22 | Insys Development Company, Inc. | Stable cannabinoid formulations |
US20160338974A1 (en) * | 2015-03-02 | 2016-11-24 | Afgin Pharma, Llc | Topical regional neuro affective therapy with cannabinoid combination products |
BR102015024165A2 (pt) | 2015-09-18 | 2017-03-28 | Prati Donaduzzi & Cia Ltda | composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso |
WO2017204986A1 (en) | 2016-05-27 | 2017-11-30 | Insys Development Company, Inc. | Stable cannabinoid formulations |
CA3027700A1 (en) | 2016-07-11 | 2018-01-18 | Intec Pharma Ltd. | Oral gastroretentive formulations and uses thereof |
GB2557921A (en) * | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
-
2018
- 2018-02-09 BR BR102018002843A patent/BR102018002843A2/pt not_active IP Right Cessation
-
2019
- 2019-02-11 CA CA3096962A patent/CA3096962A1/en active Pending
- 2019-02-11 WO PCT/BR2019/050040 patent/WO2019153064A1/pt unknown
- 2019-02-11 CN CN201980023233.4A patent/CN111936133A/zh active Pending
- 2019-02-11 EP EP19751170.2A patent/EP3750537A4/en active Pending
- 2019-02-11 JP JP2020542883A patent/JP2021512923A/ja active Pending
- 2019-02-11 BR BR112020016263-9A patent/BR112020016263A2/pt unknown
- 2019-02-11 AU AU2019217668A patent/AU2019217668A1/en active Pending
- 2019-02-11 US US16/967,334 patent/US11389423B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017519742A (ja) * | 2014-05-29 | 2017-07-20 | インシス・ファーマ・インコーポレーテッド | 安定なカンナビノイド製剤 |
US20160256410A1 (en) * | 2015-03-02 | 2016-09-08 | Afgin Pharma, Llc | Topical regional neuro-affective therapy in mammals with cannabinoids |
US20160317468A1 (en) * | 2015-04-28 | 2016-11-03 | Raman Sankar | Uses of cannabidiol for treatment of infantile spasms |
JP2020532590A (ja) * | 2017-09-01 | 2020-11-12 | ピュアフォーム グローバル インコーポレイテッド | 合成カンナビジオール組成物およびその製造方法 |
Non-Patent Citations (3)
Title |
---|
BRAIN RES., vol. 1134(1), JPN6023026081, 2007, pages 162 - 170, ISSN: 0005220360 * |
BRAZ. J. PSYCHIATRY, vol. 30(3), JPN6023026080, 2008, pages 271 - 280, ISSN: 0005220362 * |
NEUROBIOL. DIS., vol. 19(1-2), JPN6023026079, 2005, pages 96 - 107, ISSN: 0005220361 * |
Also Published As
Publication number | Publication date |
---|---|
US20200368197A1 (en) | 2020-11-26 |
EP3750537A1 (en) | 2020-12-16 |
US11389423B2 (en) | 2022-07-19 |
BR112020016263A2 (pt) | 2020-12-15 |
EP3750537A4 (en) | 2022-03-30 |
AU2019217668A1 (en) | 2020-08-27 |
BR102018002843A2 (pt) | 2019-08-27 |
WO2019153064A1 (pt) | 2019-08-15 |
CN111936133A (zh) | 2020-11-13 |
CA3096962A1 (en) | 2019-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Parkinson et al. | Co‐enzyme Q10 and idebenone use in Friedreich's ataxia | |
CA3025702C (en) | Stable cannabinoid formulations | |
JP2021512923A (ja) | 医薬組成物、組成物の添加剤及び組成物の使用 | |
US11278531B2 (en) | Combination of ibudilast and riluzole and methods of using same | |
CN108135907A (zh) | 氘化化合物和其用途 | |
CN109069645A (zh) | 用rxr激动剂与甲状腺激素的组合的肌肉疾病的治疗 | |
KR101329936B1 (ko) | 플라바논 유도체를 포함하는 피부 외용제 | |
CN114507205A (zh) | 二氢杨梅素四氢吡咯复合物及其制备方法和应用 | |
CN105963254B (zh) | 一种辅酶q10药物组合物及其制备工艺 | |
CN101904838A (zh) | 藁本内酯在制备防治老年痴呆病症组合物中的应用 | |
CN105579036B (zh) | 用于改善膀胱尿道协同失调的药剂 | |
CN112245387B (zh) | 一种重酒石酸间羟胺注射液的组成及制备方法 | |
CN106232108B (zh) | 治疗特发性肺纤维化的制药用途 | |
CN106619590B (zh) | 一种治疗神经退行性疾病的药物组合物 | |
US20150366847A1 (en) | Combination of geranylgeranylacetone and ibudilast and methods of using same | |
CN110227146A (zh) | Metrnl蛋白或基因在防治认知障碍方面的应用 | |
CN116870049B (zh) | 预防或治疗神经退行性疾病的组合物及其用途 | |
EP2686004B1 (en) | Composition comprising diamine oxidase for use in the treatment or prevention of fibromyalgia or chronic fatigue syndrome | |
CN108853086A (zh) | 儿茶素类和表儿茶素类化合物用于上调MicroRNA-150表达水平的用途 | |
US20190201376A1 (en) | Method for Treating or Preventing Fatty Acid Binding Protein 3 Induced B-amyloid Aggregation Diseases | |
Pathak et al. | Geriatric diseases of dogs and cats | |
CN115531367A (zh) | 铁死亡抑制Ferrostatin-1在糖尿病性骨质疏松症治疗药物中的应用 | |
JP2023521708A (ja) | 肥大型心筋症治療用薬学組成物およびその組成物を用いた治療方法 | |
KR20240037940A (ko) | Ppar 작용제 화합물의 사용 방법 및 이의 약학 조성물 | |
CN113616782A (zh) | 鸢尾素在治疗癫痫中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221025 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221031 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230425 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231031 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231120 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20231222 |